Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.
Jonathan D SorahDominic T MooreMatthew J ReilleyMohamed E SalemTammy TriglianosHanna K SanoffAutumn J McReeMichael S LeePublished in: The oncologist (2022)
Selection of patients for anti-EGFR rechallenge using clinical criteria alone was insufficient to identify response to palbociclib + cetuximab. Additional biomarkers are needed to select anti-EGFR rechallenge and circulating tumor DNA (ctDNA) analysis is planned for samples collected in this study. (ClinicalTrials.gov Identifier: NCT03446157).
Keyphrases
- wild type
- circulating tumor
- small cell lung cancer
- phase ii
- clinical trial
- cell free
- end stage renal disease
- circulating tumor cells
- epidermal growth factor receptor
- ejection fraction
- open label
- newly diagnosed
- tyrosine kinase
- randomized controlled trial
- chronic kidney disease
- locally advanced
- phase iii
- rectal cancer
- patient reported